DoxyPEP and gonorrhoea (MenB) vaccination

DoxyPEP (Doxycycline Post-Exposure Prophylaxis)

DoxyPEP is medication (an antibiotic) taken after sex to help prevent sexually transmitted infections (STIs) like chlamydia and syphilis. Studies have shown that DoxyPEP can significantly reduce the risk of chlamydia and syphilis (by over 70%) and to a lesser extent gonorrhoea (by around 50%) in gay, bisexual and other men who have sex with men (GBMSM). People of other genders and sexualities may be eligible too if they are at high risk of syphilis infection. The prevention dosage is 200mg of doxycycline no later than 72 hours after sex. Doxy-PEP does not protect against viruses like HIV or hepatitis B.

Vaccination against gonorrhoea

Recent research shows that the meningitis vaccine 4CMenB can reduce infections with gonorrhoea by about 40%. NHS England announced in May 2025 that the government will fund a programme of gonorrhoea vaccination in England, starting in August 2025. The vaccine programme will be available for GBMSM and transwomen who are at the highest risk of gonorrhoea. People of other genders and sexualities may be eligible too if they are at high risk of gonorrhoea infection.

You can read up more at: QueerHealth